他汀类药物治疗实验性变态反应性脑脊髓炎和多发性硬化研究进展
Research advance of treating EAE and MS with statins
出处
《中华神经医学杂志》
CAS
CSCD
2005年第9期970-972,共3页
Chinese Journal of Neuromedicine
基金
山西省2003年度归国留学人员科研基金(2003-69)
山西省培养中青年学科带头人基金(1999-60)
参考文献20
-
1Barcellos LF, Oksenberg JR, Begovich AB, et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course [J]. Am J Hum Genet, 2003, 72(3): 710-716.
-
2Kobashingawa JA, Katznelson S, Lacks H, et al. Effect ofpravastain on outcome after cardiac transplantation [J]. New Engl J Med, 1995,333(10): 621-627.
-
3Sena A, Pedrosa R, Morais MG. Therapeutic potential of lovastatin in multiple sclerosis [J]. J Neurol, 2003, 250(6): 754-755.
-
4Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease [J]. Nature, 2002, 420(6911): 78-84.
-
5Stanislaus R, Singh AK, Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis [J]. J Neurosci Res, 2001, 66(2): 155-162.
-
6Honjo M, Tanihara H, Nishijima K, et al. Statin inhibits leukocyte-endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina [J]. Arch Ophthalmol, 2002, 120(12): 1707-1713.
-
7Nath N, Giri S, Prasad R, et al. Potential targets of 3-hydroxy3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy [J]. J Immunol, 2004, 172(2): 1273-1286.
-
8Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis [J]. Lancet, 2004, 363(9421):1607-1608.
-
9Greenwood J, Walters CE, Pryce G, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis [J]. FASEB J, 2003, 17(8): 905-907.
-
10Zacco A, Togo J, Spence K, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity [J]. J Neurosci, 2003, 23(35): 11104-11111.
-
1孔德莲,周联生,葛许华,秦敬翠.阿托伐他汀对多发性硬化的治疗作用及机制探讨[J].浙江临床医学,2013,15(12):1834-1835. 被引量:1
-
2董艳玲,李吕力.多发性硬化治疗的研究进展[J].医学综述,2010,16(3):395-398. 被引量:14
-
3姜寿峰,丁美萍.多发性硬化免疫调节治疗[J].医学综述,2009,15(20):3112-3115. 被引量:1
-
4马桂云.多发性硬化症治疗药 Glatiramer[J].国外医药(合成药.生化药.制剂分册),1998,19(4):203-203.
-
5张义举.免疫球蛋白治疗急性格林-巴利综合征疗效观察[J].牡丹江医学院学报,2005,26(5):33-34. 被引量:1
-
6喻化,夏水银.喹硫平治疗首发精神分裂症68例临床观察[J].内蒙古中医药,2011,30(20):84-85. 被引量:3
-
7黄洪勇,职晓燕,王长虹.奎的平治疗首发精神分裂症临床观察[J].临床心身疾病杂志,2004,10(1):19-20. 被引量:1
-
8曹芳,付锦.对比干扰素β与醋酸格拉默治疗多发性硬化的新进展[J].中国神经免疫学和神经病学杂志,2014,21(6):419-422. 被引量:3
-
9朱琳,岳冲,于泉.醒脑静联合纳洛酮对高血压脑出血患者GCS、ADL指标的影响[J].南昌大学学报(医学版),2015,55(5):48-50. 被引量:13
-
10魏慧珍,陈国洪,刘芬.促皮质激素治疗婴儿痉挛症前后视频脑电图分析[J].中国医药科学,2015,5(22):59-61. 被引量:2